DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Trading Up 0.0 %

Shares of NASDAQ DRRX opened at $0.84 on Wednesday. The firm has a market cap of $26.08 million, a P/E ratio of -1.38 and a beta of 0.94. The business’s 50 day moving average is $0.86 and its 200-day moving average is $1.21. DURECT has a 1-year low of $0.68 and a 1-year high of $1.88.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DURECT stock. Geode Capital Management LLC lifted its holdings in shares of DURECT Co. (NASDAQ:DRRX) by 4.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 319,905 shares of the specialty pharmaceutical company’s stock after buying an additional 14,658 shares during the period. Geode Capital Management LLC owned about 1.03% of DURECT worth $429,000 as of its most recent filing with the SEC. 28.03% of the stock is owned by institutional investors.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.